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INTRODUCTION
Neuroblastoma, an embryonic tumor of 
neuroectodermal origin, accounts for 11% of all cancer-
related deaths in children [1]. Molecular aspects create 
the extreme heterogeneity of this disease, spanning 
spontaneous regression to rapid metastasizing progression 
[1, 2]. Treatment scenarios range between observation 
only and multimodal concepts including high-dose 
chemotherapy with autologous stem cell rescue, surgery, 
radiotherapy and immunotherapy [3]. Despite decades of 
considerable international efforts to improve outcome, 
long-term survival of high-risk disease remains as low 
as 20% [3]. Managing resistance to induction therapy, 
causing tumor progression and early death in ultrahigh-
risk patients, and managing chemotherapy-resistant 
relapses, which can occur years after initial diagnosis, 
remain major obstacles. MYCN amplifications [4, 5], 
telomerase activation by genomic rearrangements [6, 7], 
ATRX loss-of-function mutations or deletions [8-10] and 
germline or somatically acquired activating ALK mutations 
[11-14] define patient subgroups with highly aggressive 
and frequently therapy-resistant neuroblastomas. A 
commonality among these aggressive subgroups is that 
tumors undergo an as yet poorly understood invasion-
metastasis cascade, which may be druggable to prevent 
increasing metastatic colonization.
Tetraspanin proteins all have four membrane-
spanning domains, and form clusters between themselves 
and a large variety of molecules, predominantly including 
integrins, proteases and gangliosides. Tetraspanins can 
become engaged in signal transduction by recruiting 
cytoplas- mic kinases to the glycolipid- and cholesterol-
enriched membrane microdomains to which they are 
localized [15-17]. CD9 tetraspanin expression strongly 
varies among different organs, with the highest expression 
found in endocrine tissues and the gastrointestinal tract, 
and the lowest expression reported both in liver and gall 
bladder [18]. Here, we assessed the significance of CD9 
expression in primary neuroblastomas using clinical and 
molecular tumor data, unraveled the upstream activating 
and repressive control including epigenetic events and 
analyzed the functional role of CD9 using targeted CD9 
re-expression in cell and animal models of neuroblastoma. 
RESULTS
GRHL1 is a transcriptional activator of CD9
High-level GRHL1 expression favorably influences 
neuroblastoma biology at the molecular and phenotypic 
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migration-invasion-metastasis cascade would be of great benefit, but the mechanisms 
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player and direct target of the recently described GRHL1 tumor suppressor. CD9 is 
known to block or facilitate cancer cell motility and metastasis dependent upon entity. 
High-level CD9 expression in primary neuroblastomas correlated with patient survival 
and established markers for favorable disease. Low-level CD9 expression was an 
independent risk factor for adverse outcome. MYCN and HDAC5 colocalized to the CD9 
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tumor development in the TH-MYCN transgenic mouse model for neuroblastoma, and 
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promoter methylation in methyl-CpG-binding domain sequencing analyses, and high-
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levels [19]. Time-resolved whole-genome expression 
analyses on BE(2)-C cells transfected with empty- or 
GRHL1 vectors resulted in differential regulation over 
time of 170 genes, including CD9 [19]. Increasing CD9 
expression following enforced GRHL1 expression in 
BE(2)-C cells was confirmed both on the mRNA level 
by qRT-PCR and on the protein level by western blot 
analysis (Figure 1A). Transient knockdown of GRHL1 
in SH-EP cells by two different siRNAs to control for 
unspecific and off-target effects reduced CD9 expression 
by approximately 50% (Figure 1B). We next conducted 
ChIP-qPCR using an antibody against the FLAG tag 
of FLAG-GRHL1 in overexpressing BE(2)-C cells to 
assess whether GRHL1 is recruited to the CD9 promoter 
region (Figure 1C). GRHL1 was significantly enriched 
(Figure 1D) above the control (ChIP for IgG) in the CD9 
transcriptional start site distal to a previously described 
SP1 binding site [20] and proximal to a MYC binding 
site (http://genome.ucsc.edu). We conclude that GRHL1 
activates CD9 transcription in neuroblastoma cells. 
High-level CD9 expression in neuroblastomas 
predicts favorable survival as an independent 
prognostic marker
Having shown that CD9 is downstream of 
GRHL1 in neuroblastoma cells, we assessed whether 
CD9 is differentially expressed in primary tumors. We 
reanalyzed microarray expression data from a cohort 
of 476 neuroblastomas [21]. Kaplan-Meier analysis 
showed that high-level CD9 expression in tumors, 
irregardless of International Neuroblastoma Staging 
System (INSS) stage or patient age, correlated both with 
favorable event-free and overall patient survival (Figure 
2A-2F and Supplementary Figure S1A-S1D). These 
correlations were confirmed in microarray expression 
data from an independent cohort of 122 neuroblastomas 
[22] (Supplementary Figure S2A-S2D). High-level CD9 
expression in neuroblastomas from the 476-tumor cohort 
also significantly correlated with established clinical and 
molecular markers for favorable tumor biology, including 
INSS localized or 4S disease stages, age at diagnosis ≤ 18 
months, favorable Shimada/International Neuroblastoma 
Pathology Classification (INPC) tumor histology, lack 
of MYCN amplifications or 1p aberrations and a low-
Figure 1: GRHL1 triggers CD9 expression. A., CD9 expression in BE(2)-C cells 24h-72h after GRHL1 plasmid or empty-vector 
transfection on mRNA (upper panel; qRT-PCR; mean ± SD; n = 3) and protein level (lower panel; western blot). B., CD9 expression in 
SH-EP cells 96h after GRHL1 knockdown with small interfering RNAs (si-1, si-2) (upper panel; qRT-PCR; mean fold-change over mock 
± SD; n = 3). Controls were transfected with two different negative control siRNAs (siNC-1, siNC-2). GRHL1 knockdown efficacy was 
measured by western blot at 96h (lower panel) while CD9 protein expression in SH-EP was below detection. Histone H3 served as loading 
control. C., schematic representation of the CD9 promoter indicating the primer positions (arrows), the transcriptional start site (TSS) and 
the localization of previously described binding sites for SP1 and MYC. D., the mean enrichment (± SD, n = 3) of CD9 promoter DNA 
associated with GRHL1 is shown from ChIP-qPCR experiments. BE(2)-C cells from GRHL1 transfected cells were immunoprecipitated 
with antibodies against FLAG-GRHL1 or IgG, as negative control, and 0.1% input lysate served as normalization for comparing ChIPs 
(mean ± SD, n = 3). *P < 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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risk tumor transcriptional profile previously defined by 
PAM analysis [23] (Figure 2G-2L). Correlations between 
elevated CD9 tumor expression and all available clinical 
and molecular parameters for favorable tumor biology 
were confirmed in the 122-tumor cohort (Supplementary 
Figure S2E-S2H). These included localized INSS 
localized or 4S disease stages, age at diagnosis ≤ 18 
months, lack of MYCN amplifications or 1p aberrations. 
Multivariate survival analysis was performed in the 
476-tumor cohort to determine whether CD9 expression 
provides additional predictive power over established 
clinical and molecular prognostic markers. Established 
risk factors were associated both with favorable event-
free and overall survival in univariate survival analyses 
(Supplementary Table S3) and the prognostic value of 
CD9 expression was independent of these established 
risk markers in multivariate analyses testing all factors 
together (event-free survival, P = 0.001; overall survival, 
P = 0.005; Supplementary Table S3). Taken together, 
high-level CD9 expression in primary neuroblastomas 
signals a favorable tumor biology and patient prognosis 
independent of established clinical and molecular risk 
factors. 
MYCN is a transcriptional repressor of CD9
A major factor influencing neuroblastoma biology is 
the MYCN status in the tumor, which inversely correlated 
with CD9 expression in primary neuroblastomas 
(Figure 2J, Supplementary Figure S2G). Kaplan-
Meier analyses comparing the predictive power of 
CD9 expression in tumors lacking or harboring MYCN 
amplifications produced only a significant correlation 
between high CD9 expression and favorable event-
free and overall survival in the patient cohort with 
tumors lacking MYCN amplifications (Figure 3A-3D), 
suggesting that MYCN may be upstream of CD9. To 
assess whether differential CD9 expression in primary 
neuroblastomas with and without MYCN amplifications 
(Figure 2J, Supplementary Figure S2G) is mirrored at 
the protein level, we semiquantified CD9 expression 
immunohistochemically in 20 selected samples from 
tumors with the most divergent characteristics. Tumors 
lacking MYCN amplifications expressed CD9 in a variably 
strong manner, and expression was localized to the cell 
membrane, whereas no CD9 expression was detected in 
any of the MYCN-amplified tumors (Figure 3E-3F). We 
investigated CD9 gene methylation status by reanalyzing 
existing methyl-CpG-binding domain sequencing data 
from 60 neuroblastomas [24, 25]. The CD9 promoter 
was differentially methylated within the group of tumors 
lacking MYCN amplifications (n = 43), and high-level 
promoter methylation was associated with advanced stage 
disease as defined by INSS stages 3 and 4 (Figure 3G). 
These results confirm the inverse correlation between 
MYCN status and CD9 expression at the protein level 
and point towards a functional role of CD9 promoter 
methylation in tumors lacking MYCN amplifications. We 
next used several different neuroblastoma cell and mouse 
models to investigate the nature of this relationship and 
the influence of MYCN on CD9 expression. We analyzed 
changes in CD9 expression occurring between 4h to 48h 
in the synthetic MYCN-inducible system, SH-EP Tet-
21/N. Conditional MYCN expression downregulated CD9 
expression by approximately 15% after 4h and by 50% 
after 24h (Figure 4A). Endogenous MYCN expression 
was depleted in BE(2)-C cells by transient expression 
of a short hairpin RNA (shRNA) plasmid directed 
against MYCN. CD9 expression increased between 24h 
and 72h time-dependently, reaching a 2-fold increase in 
CD9 mRNA expression and a 2.4-fold increase in CD9 
protein expression (Figure 4B). Results from these two 
models suggest that MYCN suppresses CD9 expression. 
We performed ChiP-qPCR experiments to test whether 
MYCN directly associates with the CD9 promoter. Not 
only was MYCN enriched in the CD9 promoter (compare 
Figure 4C with Figure 1C), but this enrichment was 
confined to the region enriched for GRHL1 (Figure 1D). 
We have previously shown that MYCN is a transcriptional 
repressor of GRHL1 [19]. To test whether GRHL1 
is required for CD9 induction mediated by MYCN 
depletion, we transiently knocked down both GRHL1 
and MYCN in BE(2)-C. Transient GRHL1 knockdown 
diminished induction of the CD9 transcript by MYCN 
depletion by 35%, indicating that GRHL1 contributes to 
CD9 transcriptional activating when silencing MYCN 
(Figure 4D). We next used the TH-MYCN neuroblastoma 
progression model to analyze the temporal CD9 expression 
pattern. CD9 expression was strongly reduced during 
progressive development of neuroblastic tumors in TH-
MYCN+/+ mice and remained far below CD9 expression 
in ganglia from wildtype TH-MYCN-/- mice (Figure 4E). 
Collectively, our data argue for a role of MYCN in the 
transcriptional repression of CD9 in neuroblastoma cells. 
HDAC5 negatively regulates CD9 and combined 
inhibition of HDAC5 and DNA MTases 
synergistically induces CD9
A model for transcriptional repression via MYCN 
involves histone deacetylase (HDAC) recruitment 
to promoter regions. To identify HDACs potentially 
involved in CD9 transcriptional repression, we transiently 
knocked down each of the eleven HDACs (using two 
different siRNAs for each to control for unspecific and 
off-target effects, Supplementary Table S2) belonging to 
classes I, II a/b and IV in BE(2)-C cells, then assessed 
CD9 expression. Only HDAC5 depletion induced CD9 
expression, which reached 1.7- to 2.3-fold of the control 
96h after knockdown (Figure 5A). Depleting HDACs 
1, 4, 6, 7, 8, 9 and 11 did not affect CD9 expression, 
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Figure 2: High-level CD9 expression in primary neuroblastomas predicts favorable patient survival in a cohort of 
476 tumors and correlates with favorable established clinical and molecular markers. Kaplan-Meier analysis of event-free 
A.-C. and overall patient survival D.-F. irregardless of INSS stage A., D. and in INSS stage 3 B., E. and stage 4 patients C., F. Box-plots 
compare CD9 expression in tumors with varying stages according to INSS G., in tumors from patients with age at diagnosis under or over 
18 months H., in tumors with favorable or unfavorable classification according to Shimada/INPC I., in tumors either lacking or harboring 
MYCN amplifications J., in tumors either lacking or harboring 1p aberrations K., and in tumors classified either as low or high risk by a 
PAM classifier using microarray expression profiles L. 
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Figure 3: MYCN status and CD9 expression inversely correlate in primary neuroblastomas, and CD9 promoter 
hypermethylation is associated with advanced stage disease in tumors lacking MYCN amplifications. A.-D., high-level 
CD9 expression in MYCN single-copy but not in MYCN-amplified tumors predicts favorable patient survival in a cohort of 476 tumors. 
Kaplan-Meier analysis of event-free A.-B. and overall C.-D. patient survival. E.-F., the differential pattern of CD9 expression is translated to 
the protein level in neuroblastomas having the most divergent tumor biologies. CD9 immunohistochemical staining (brown) is exemplarily 
shown E. for a low-risk INSS stage 1 ganglioneuroblastoma lacking MYCN amplification and an INSS stage 4 poorly differentiated high-
risk neuroblastoma harboring a MYCN amplification. CD9 expression was semi-quantitatively analyzed, and the data for all 20 tumors 
were presented as box-plots comparing the MYCN single-copy and MYCN-amplified tumor groups F. G., Box-plots compare CD9 promoter 
(chr12: 6308102-6310102; Human Genome Issue HG-19) normalized read counts of methyl-CpG-binding domain (MBD) sequencing data 
in high- (INSS stages 3 and 4) versus low stage MYCN single copy primary neuroblastomas (INSS stages 1, 2 and 4S).
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while depleting HDACs 2, 3 and 10 decreased CD9 
levels (Figure 5A), suggesting HDACs 2, 3 and 10 may 
counteract HDAC5 influence on CD9 expression. To test 
whether HDAC5 is recruited to the CD9 promoter site, we 
performed ChIP-qPCRs using anti-FLAG M2-conjugated 
agarose to capture immunocomplexes after HDAC5-
FLAG enforced expression in BE(2)-C cells. HDAC5 
was enriched by ~3.5-fold at the CD9 promoter (compare 
Figure 5B with Figure 1C), and localized to the region 
where GRHL1 was also enriched as a transcriptional 
activator and MYCN was enriched as a transcriptional 
repressor. 
As an alternative approach to HDAC5 knockdown, 
we treated BE(2)-C cells with a variety of small molecule 
HDAC inhibitors, then assessed CD9 expression. CD9 
induction by the clinically approved pan-HDAC inhibitor, 
Figure 4: MYCN inhibits CD9 expression. A.-B., CD9 expression was assessed on the mRNA (qRT-PCR; mean ± SD, n = 3) and 
protein level (western blots) in the synthetic MYCN-inducible SH-EP Tet-21/N cell model with/without MYCN induction in time-course 
A. and in BE(2)-C at designated time points after MYCN depletion B. CD9 protein expression in SH-EP Tet-21/N was below detection. 
GAPDH served as loading control. C., ChIP-qPCR showing an enrichment of CD9 promoter DNA associated with MYCN. BE(2)-C lysates 
were immunoprecipitated with antibodies against MYCN or IgG, as negative control, and 0.1% of the input served for normalization (mean 
± SD, n = 3). D., CD9 expression was assessed on the mRNA level (qRT-PCR; mean ± SD, n = 3) in BE(2)-C 96h after GRHL1 knockdown 
using a small interfering RNA (si-1) and 72h after MYCN depletion using a short hairpin RNA (shRNA) directed against MYCN. Controls 
were transfected with respective negative control siRNA and empty vector. E., the expression of Cd9 during neuroblastoma progression 
from tumor-prone ganglia to tumors in transgenic mice (n = 4; full line) and in comparison to Cd9 expression in wild-type ganglia (n = 4; 
dashed line). Linear regression analysis; P = 4.7x10-11; delta slope = -1.1. *P < 0.05, **P ≤ 0.01.
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Figure 5: HDAC5 negatively regulates CD9, and combined DAC/HDAC inhibitor treatment synergistically triggers 
CD9 expression. A., RNAi targeting HDACS 1-11 singly in BE(2)-C cells with siRNAs (si-1, si-2). Control were transfected with 
two different negative control siRNAs (siNC-1, siNC-2). CD9 expression was measured by qRT-PCR 96 hours after transfection and is 
represented as mean fold-change over mock control ± SD (n ≥ 2). B., ChIP-qPCR (mean ± SD, n = 3) showing an enrichment of CD9 
promoter DNA associated with HDAC5. BE(2)-C lysates were immunoprecipitated with an antibody against HDAC5 or IgG as negative 
control. C., CD9 expression (assessed by qRT-PCR and Western blotting) after treating BE(2)-C cells with panobinostat (5 nM, 10 nM, 15 
nM, 20 nM), vorinostat ( 0.5 µM, 1 µM), 5 µM tubacin (Tub), 20 µM compound 2 (Cpd2), 30 µM bufexamac (Buf) or respective solvent 
controls for 48 hours (mean fold-change over control ± SD is shown, n ≥ 3). D., CD9 expression (assessed by qRT-PCR and Western 
blotting) in BE(2)-C cells transfected with HDAC5 or empty vector for 72h and treated with 15 nM panobinostat or solvent control for 
48h. GAPDH served as loading control. E., CD9 expression (assessed by qRT-PCR) in BE(2)-C cells treated up to 12 hours with 1 µg/ml 
Actinomycin D, 20 nM panobinostat or solvent control (n = 3). F., the mean enrichment (±SD, n = 3) of CD9 promoter DNA associated 
with pan-acetylated histone H4 after 5 hours of 20 nM panobinostat treatment is shown from ChIP-qPCR experiments. BE(2)-C lysates 
were immunoprecipitated with an antibody against pan-acetylated histone H4, and 0.1% input lysate was used as a loading control for 
comparing ChIPs. G.-H., CD9 expression was assessed on the mRNA (qRT-PCR; mean ± SD, n = 3) and protein level (western blotting) in 
the neuroblastoma cell lines BE(2)-C G. and SH-EP H. 96 hours after treatment with 3 µM DAC, 10 nM panobinostat or combined 3 µM 
DAC/10 nM panobinostat treatment. β-actin served as loading control. I., CD9 expression in the neuroblastoma cell lines IMR-32, Kelly 
and SH-SY5Y 48 hours after combined treatment with 3 µM DAC and 5 (IMR-32) - 10 nM panobinostat (Kelly, SH-SY5Y) or solvent 
controls. J, RNA and protein were isolated from BE(2)-C cells 48 hours after combined treatment with 3 µM DAC/10 nM panobinostat 
or solvent controls under normoxia (21% O2) versus hypoxia (3% O2), serum substitution (10% FCS) versus starvation (0.1% FCS) and 
normal condition versus genotoxic stress (0.1 µg/ml doxorubicin). CD9 expression was measured at the mRNA and protein levels using 
qRT-PCR (mean fold-change over solvent ± SD, n = 3) and western blotting. DAC, 5-aza-2’-deoxycytidine. *P < 0.05; **P ≤ 0.01; ***P ≤ 
0.001; #P = 0.0131 for BE(2)-C and P ≤ 0.0001 for SH-EP.
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panobinostat, was dose-dependent, and ranged between 
2.3- and 3.8-fold on the mRNA level and between 2- 
and 5.3-fold on the protein level (Figure 5C). Another 
clinically approved HDAC-inhibitor, vorinostat, weakly 
inhibited HDAC5, and only induced CD9 expression by 
1.4-fold and CD9 protein levels by 2-fold (Figure 5C). 
CD9 mRNA or protein expression was not induced by the 
HDAC6-selective inhibitor, tubacin; the HDAC8-selective 
inhibitor, compound 2; or by bufexamac, which inhibits 
both HDAC6 and HDAC10 (Figure 5C). To test whether 
enforced HDAC5 expression could at least partially 
counteract CD9 induction by HDAC inhibitor treatment, 
BE(2)-C, Kelly and SH-EP cells were transiently 
transfected with a HDAC5 expression vector then 
treated with panobinostat. Enforced HDAC5 expression 
decreased the CD9 induction triggered by panobinostat 
Figure 6: High-level CD9 expression inhibits migration and invasion of neuroblastoma cells in Boyden chambers and 
metastatic disease to the chicken embryo bone marrow. The stable CD9-inducible SH-EP cell model and the respective stable 
control cells were used to determine the effect of CD9 expression on migration A.-C. and invasion D.-F. Migration/invasion was measured 
with the xCELLigence Real-Time Cell Analyzer (n = 3 in quadruplicate). E., number of metastasizing BE(2)-C cells with and without 
enforced CD9 expression in the bone marrow chicken embryos. Cells were transplanted onto the chorioallantoic membranes of fertilized 
pathogen-free leghorn eggs (n ≥ 11 per study group). On day 17, the embryos were sacrificed, and the bone marrow was isolated. Human 
ALU sequences were amplified and quantified by qRT-PCR. n.s., not significant; *P < 0.05; ***P ≤ 0 .001. 
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up to 15% on both transcript and protein levels (Figure 
5D, Supplementary Figure S3A-S3B), demonstrating 
that the effect of pan-HDAC inhibition could be 
partially outcompeted by HDAC5 overexpression. To 
differentiate between de novo transcript synthesis and 
increased transcript stability, we cotreated BE(2)-C cells 
with actinomycin D and panobinostat or solvent control 
for up to 12h. Blocking de novo RNA synthesis with 
actinomycin D resulted in equivalent CD9 expression in 
cells treated with HDAC inhibitor and untreated control 
cells, confirming that control is enacted via transcriptional 
activation (Figure 5E). To examine epigenetic changes 
prior to CD9 transcriptional activation, we performed 
chromatin immunoprecipitation (ChIP) in BE(2)-C 
cells treated for 5h with panobinostat or solvent control 
using an antibody against pan-acetylated histone H4, and 
looked for changes in the CD9 promoter. We detected 
an increase in pan-acetylated histone H4 associated with 
the transcriptional start site of the CD9 gene after HDAC 
inhibitor treatment, indicating that epigenetic changes 
preceded transcriptional activation (compare Figure 5F 
with Figure 1C). Taken together, CD9 is epigenetically and 
transcriptionally repressed by the chromatin-modifying 
enzyme, HDAC5, in association with MYCN, and CD9 
expression can be triggered in neuroblastoma cells by 
inhibition of HDAC5.
Next, we assessed whether co-treatment with a 
nucleoside inhibitor of DNA methylation, 5-Aza-2’-
deoxycytidine (DAC), could enhance transcriptional 
activation. Combined treatment of BE(2)-C and SH-
EP neuroblastoma cells with panobinostat and DAC 
synergistically induced CD9 up to 8-fold on the transcript 
and 6.5-fold on the protein levels (Figure 5G-5H). We 
also achieved similar results using the IMR-32, Kelly and 
SH-SY5Y neuroblastoma cell lines (Figure 5I). We next 
analyzed the effectiveness of CD9 induction in BE(2)-C 
cells by combined panobinostat/DAC treatment under 
conditions mimicking those in tumors such as hypoxia, 
starvation and stress induced by cytotoxic drugs such 
as doxorubicin. Starvation caused by culture for 72h in 
serum-free medium strongly reduced endogenous CD9 
levels, while both hypoxia and genotoxic stress had 
no major effect on CD9 expression (Figure 5J). Drug 
treatment triggered CD9 expression by 4- to 5-fold 
compared to controls in all culture conditions (Figure 5J), 
suggesting transcription can still be robustly activated. Our 
data argue a role for HDAC5 in transcriptionally repressing 
CD9 in neuroblastoma cells beyond the repression 
achieved by MYCN and DNA methyltransferases, and 
offers an avenue for pharmacological intervention. 
Figure 7: Schematic model summarizing the expression, regulation and function of CD9 in neuroblastoma and 
indicating the experimental strategies applied.
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CD9 attenuates neuroblastoma cell migration, 
invasion and metastasis formation
Data obtained from primary tumors suggested that 
high-level CD9 expression is associated with favorable 
tumor biology. To investigate whether high-level CD9 
expression exerts its antitumorigenic effect via influencing 
proliferation and viability, SH-EP cells stably transfected 
with an inducible CD9 construct or a negative control 
expression system (Supplementary Figure S4A-S4B) 
were analyzed in proliferation assays. CD9 induction 
did not significantly alter cell proliferation or viability 
in the SH-EP cell model (Supplementary Figure S5A-
S5B). Similarly, transient enforced CD9 expression did 
not alter BE(2)-C cell proliferation or viability compared 
to control cells transfected with empty or LacZ vectors 
(Supplementary Figure S4C-S4D and Supp- lementary 
Figure S5C-S5D). Xenograft tumor take or growth rate 
was also not influenced by prior transient transfection 
with either CD9 or LacZ control vector in BE(2)-C 
cells subcutaneously implanted into CB17-SCID mice 
(Supplementary Figure S5E). These experiments strongly 
indicate that CD9 exerts its antitumoral effects via 
other avenues than influencing tumor cell proliferation. 
To investigate whether migratory or invasive capacity 
was affected, we functionally analyzed the phenotypic 
consequences of inducing CD9 expression in the SH-EP 
cell model during Boyden chamber migration and invasion 
assays. Inducing CD9 expression reduced cell migration 
by 40%, while inducing the negative control expression 
system produced no difference in cell migration (Figure 
6A-6C). Similarly, CD9 induction inhibited invasion 
capacity by 40%, while inducing the negative control 
expression system again had no effect (Figure 6D-6F). 
We next evaluated whether our in vitro findings were also 
applicable in the in vivo chicken embryo chorioallantoic 
membrane metastasis assay. The number of BE(2)-C cells 
that metastasized from the chorioallantoic membrane 
to the chicken embryonic bone marrow was strongly 
reduced by enforced CD9 expression compared with 
empty vector-transfected control cells (Figure 6G). SH-
EP cells, which do not metastasize in the chicken embryo 
chorioallantoic membrane metastasis assay, were not 
investigated. Transient enforced expression was applied in 
BE(2)-C cells as inducible gene expression by tetracycline 
addition is technically not feasible in the chicken embryo 
chorioallantoic membrane metastasis assay. Taken 
together, our data supports a mode of action by CD9, in 
which high-level expression in neuroblastoma cells exerts 
an antitumoral effect by inhibiting several different steps 
in the invasion-metastasis cascade (schematic model 
shown in Figure 7).
DISCUSSION
This study identified CD9 as a critical and indirectly 
druggable node in the neuroblastoma invasion-metastasis 
cascade. This is of particular interest since widespread and 
extensive metastatic burden causes most neuroblastoma-
related deaths, mirroring the perception that activating 
invasion and metastasis belongs to the cancer hallmarks 
acquired during the multistep development of human 
tumors [26]. Suppressing neuroblastoma metastasis would, 
taken in this light, be a top priority to improve survival 
of high-risk disease with targeted therapeutic approaches. 
Neuroblastoma originates from aberrant neural 
crest progenitor cells, which physiologically give rise 
both to sympathetic neurons and chromaffin cells of 
the adrenal glands [1, 2] . A review of the literature 
indicates that CD9 is expressed in early neural crest-
derived embryonic rat sympathetic neurons and adrenal 
chromaffin cells. CD9 expression is also sustained 
throughout adulthood, localized to the surface of nerve 
cell bodies, axons and growth cones [27]. Yet, so far, 
no role for CD9 has been described in neuroblastoma 
pathogenesis. We detected low-level CD9 expression in 
primary neuroblastomas that correlated with metastasized 
high-risk disease, low probability of patient survival and 
established clinical and molecular markers for unfavorable 
disease including MYCN amplification in the tumor. 
High-level CD9 expression in primary neuroblastomas 
served as an independent favorable prognostic marker. 
Patients stratified into subgroups based on different CD9 
expression levels in the tumors also segregated known 
prognostic markers such as age at diagnosis ( ≤ or > 18 
months), and INSS tumor stages 3 or 4 versus stages 1, 2 
or 4S. The major strength of CD9 tumor expression as a 
novel prognostic marker may be its potential for predicting 
disease progression in neuroblastoma patient subgroups. 
Using functional assays, we demonstrated that 
CD9 suppresses neuroblastoma cell migration and 
invasion. This is in line with evidence from studies 
with ovarian [28] and bladder carcinoma cell lines 
[29] that low-level CD9 expression triggers tumor cell 
motility and invasiveness. On a molecular level, CD9 
is known to inhibit integrin-mediated motility and 
associate with the platelet aggregation-inducting factor 
podoplanin, thereby preventing platelet aggregation and, 
consequently, a tumor-cell protective microenvironment 
(reviewed in [30]). We moved beyond in vitro assays 
for invasion and metastasis, to an in vivo model where 
human neuroblastoma cells explanted to the chicken 
chorioallantoic membrane invade the chicken embryo bone 
marrow, thus, reflecting human neuroblastoma metastatic 
behavior. Enforced CD9 expression strongly inhibited the 
number of neuroblastoma cells metastasized to the chicken 
bone marrow demonstrating that CD9 acts to inhibit the 
invasion-metastasis cascade in an in vivo neuroblastoma 
model. These data indicate that pharmacological strategies 
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to raise CD9 expression in the tumor could potentially 
prevent an increasing burden of metastatic colonization in 
high-risk neuroblastoma patients. 
Here we identified GRHL1 as a transcriptional 
activator of the CD9 gene and showed that MYCN and 
HDAC5 transcriptionally repress CD9 in neuroblastoma. 
Our experiments with histone deacetylase inhibitors 
demonstrated the potential indirect druggability of 
CD9. Statistical models identified the synergistic 
effect of combining an HDAC inhibitor and the DNA 
methyltransferase inhibitor, 5′-azadeoxycytidine, 
supporting the observation that epigenetic events can be 
remodeled by pharmacological intervention. Previous 
investigations by us and others [31-35] have delineated 
and deciphered specific functions of single HDACs 
in neuroblastomas with defined molecular profiles. 
We showed that HDAC2 cooperates with MYCN to 
suppress apoptosis mediated by miR-183 [36], and 
that HDAC3 interacts with MYCN to transcriptionally 
repress the GRHL1 transcription factor, which exerts 
tumor suppressive effects in neuroblastoma [19]. We 
demonstrated that HDAC8 inhibits neuroblastoma cell 
differentiation [37] and HDAC10 promotes autophagy-
mediated neuroblastoma cell survival [38]. We detected 
elevated levels of HDAC11 expression in neuroblastomas 
and several carcinomas compared to corresponding 
healthy tissues, and showed that HDAC11 depletion 
was sufficient to cause apoptosis and inhibit metabolic 
activity in different cancer cell lines, representing major 
oncological indications for industrial drug development 
programs [39]. Beyond the previously described 
specific and non-redundant oncogenic functions of 
HDAC2, HDAC3, HDAC8, HDAC10 and HDAC11 in 
neuroblastoma pathophysiology, this study defines a role 
for HDAC5 in triggering the invasion-metastasis cascade 
in neuroblastoma. 
As we are only at the beginning of understanding 
the potential therapeutic use of HDAC inhibition 
strategies and their combination within complex rationales 
utilizing several epigenetic-cancer therapies, further 
studies are required to define how to best construct drug 
strategies targeting epigenetic players such as HDACs 
and bromodomain and extra-terminal domain (BET) 
protein family members. Taken together, the present 
study (i) identifies low-level CD9 expression as a novel 
prognostic marker in high-risk neuroblastoma patient 
subgroups, (ii) exposes CD9 transcriptional activation 
by GRHL1 and its repression by MYCN and HDAC5, 
(iii) defines the potential of high-level CD9 expression 
to interrupt the neuroblastoma invasion-metastatic 
cascade and (iv) demonstrates the indirect druggability 
of CD9 by combined inhibition of HDAC5 and DNA 
methyltransferase inhibitors. 
MATERIALS AND METHODS
Tumor samples and cell culture
Formalin-fixed, paraffin-embedded samples 
from 20 primary neuroblastomas (13 localized or 
stage 4S and 7 stage 4, 3 of which harboring MYCN 
amplifications) available from patients in the NB2004 
trial (informed consent available) were selected for CD9 
immunohistochemistry. Authenticated neuroblastoma cell 
lines and models were maintained under standard cell 
culture conditions. Details are supplied in Supplementary 
Materials and Methods. 
Quantitative reverse-transcriptase real-time PCR 
(qRT-PCR)
Total RNA was isolated from cell lines using 
the RNeasy Mini Kit (Qiagen). The Thermo Scientific 
First Strand cDNA Synthesis Kit was used to transcribe 
cDNAs for qRT-PCR analysis. Relative gene expression 
was measured in qRT-PCR using SYBR Green Dye 
(Eurogentec) and primers (Supplementary Table S1) on 
an ABI Prism 7500 thermal cycler (Perkin-Elmer Applied 
Biosystems), and normalized to the averaged expression of 
ACTB and 18S rRNA or the averaged expression of SDHA 
and HPRT1, a gene pair that is consistently expressed in 
stage 4 and 4S neuroblastomas [40]. Data were analyzed 
using Applied Biosystems 7500 software v2.0.5, and 
changes in expression were calculated using the ΔΔCt 
method [41]. 
In vitro cell migration and invasion
Migration and invasion of cells was measured 
using the CIM-Plate 16 Boyden chamber system (ACEA 
Biosciences) and the xCELLigence Real-Time Cell 
Analyzer (ACEA Biosciences) [42, 43]. Boyden chambers 
were prepared for invasion assays by adding 160µl FCS-
containing medium to the lower chamber and successively 
adding 50µl serum-free medium, 20µl Matrigel diluted 
1:40 in serum-free medium followed by 4h at 37°C, 5% 
CO2 and 30µl serum-free medium above the Matrigel to 
the upper chamber. After 24h in serum-free medium, 6x104 
cells were seeded into the upper chamber, and migrating/
invading cells were monitored by serial impedance 
measurements [42, 43]. Assays were performed in 
quadruplicate and repeated three times. Cell migration and 
invasion were calculated using RTCA Software version 
2.0 (ACEA Biosciences). 
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TaqMan®-based chicken embryo metastasis assay
Fertilized patho gen-free leghorn eggs (Charles 
River) were incubated at 37ºC in 60% humidity with 
rotation in a Marsh Incubator (Lyon Electric). The 
allontoic vein was localized at day 10, over which a 
window was cut in the shell using a miniaturized rotating 
electric saw (Dremel) after removing air from the natural 
air space under mild vacuum pressure. Single-cell 
suspensions of empty vector- or CD9 plasmid-transfected 
BE(2)-C cells were prepared in serum-free medium, 2x106 
cells inoculated onto each chorioallantoic membrane 
and the windows sealed with cellotape. Embryos were 
sacrificed on day 17 (n = 18 per study group), and bone 
marrow was isolated and snap frozen for preparation of 
genomic DNA. The TaqMan-based ALU assay takes 
advantage of the abundantly present ALU family of short 
interspersed repeated DNA elements in the human genome 
to identify human DNA [44]. PCR reactions were carried 
out as described [45] using 2x qRT-PCR MasterMix 
(Eurogentec) and primers for YB8-ALU-S68, YB8-ALU-
AS244 and YB8-ALU-167 (Supplementary Table 1). A 
standard curve was generated from DNA samples from 
10,000, 1000, 100, 10 and 0 BE(2)-C cells mixed with 
1µg of chicken liver genomic DNA each to quantify the 
BE(2)-C cells metastasized to the chicken bone marrow. 
TH-MYCN neuroblastoma progression model
TH-MYCN+/+ mice [46] were sacrificed at day 7 
(n = 4) and day 14 (n = 4) of life to harvest sympathetic 
ganglia containing hyperplastic neuroblast foci, and at 
week 6 of life to harvest advanced neuroblastic tumors 
(n = 4). Sympathetic ganglia were also dissected from 
TH-MYCN-/- mice at day 7 (n = 4), day 14 (n = 4) and 
week 6 (n = 4) of life to assess gene expression changes 
during normal development. Total RNA was isolated using 
the miRNeasy Mini Kit, and samples profiled on Agilent 
SurePrint G3 Gene Expression Microarrays according to 
the manufacturers’ protocols. Data were summarized and 
normalized with the vsn method [47] in the R statistical 
programming language [48] using the limma package 
[49]. Linear regression analysis was performed to evaluate 
differential temporal expression in ganglia from wildtype 
mice and ganglia and tumors from transgenic mice. 
Subcutaneous BE(2)-C xenograft tumor model in 
CB17-SCID mice
BE(2)-C cells were transfected for 24h with 
LacZ- or CD9-vectors in culture, then 2x 106 viable 
cells suspended in 200µl Matrigel (BD Biosciences) 
were subcutaneously implanted in the flanks of 6-week 
old female CB17-SCID mice (n = 12 per study group). 
Animals were sacrificed 13 days after grafting. Tumor 
size was measured daily with a caliper, and volume 
calculated by π/6(w1×w2×w2), where w1 equals largest 
tumor diameter, and w2 equals smallest tumor diameter. 
Experiments conformed to regulatory standards and were 
approved by the local ethics committee.
Data analysis
CD9 mRNA expression values were calculated 
using existing whole-genome expression profiles from 
476 primary neuroblastomas [21], and validated using 
whole-genome expression profiles from 122 further 
neuroblastomas [22]. Kaplan-Meier curves were 
generated for the 476 neuroblastoma cohort using the R 
Survival package and compared using log-rank testing. 
The CD9 probesets with the highest average signal were 
selected for analysis. Relapse, progression and death from 
disease were considered events for calculation of event-
free survival. Both overall and event-free survival were 
calculated from the time of diagnosis to death, event or 
last examination. Optimal cut-offs for overall and event-
free survival analyses were calculated using the R Maxstat 
package according to the method defined by Lausen and 
Schumacher [50] determining the expression value best 
separating outcome into two groups using a maximally 
selected two-sample log-rank statistic. Optimal cut-offs 
were 4774.47 (overall survival) and 5330.71 (event-free 
survival). Results were corrected for multiple testing. 
CD9 expression between two patient subgroups were 
compared using the Mann-Whitney U test. Univariate 
and multivariate analyses were performed for overall 
and event-free survival using Cox proportional hazards 
regression models using SPSS (IBM, 20.0.0 release) 
or R (version 3.0.1). The R2 platform (http://r2.amc.
nl) was used to generate Kaplan-Meier survival curves 
and box plots of CD9 expression comparisons for the 
122-neuroblastoma cohort [22]. CD9 gene methylation 
status was derived from existing methyl-CpG-binding 
domain sequencing data from 60 internationally collected 
primary neuroblastoma samples [24, 25]. Single values 
from cell culture experiments were compared using 
the one-sample t-test in GraphPad Prism version 5.0 
(GraphPad Software Inc., La Jolla, CA). CD9 expression 
in cell groups transfected with either of two negative 
controls or either of two HDAC-specific siRNAs were 
compared using a mixed linear model with fixed-factor 
treatment and random intercept for each siRNA using SAS 
PROC MIXED, Version 9.2 (SAS Institute Inc., Cary, NC, 
USA). Delta-Ct values were evaluated by a two-factorial 
mixed linear model with interaction and random effect 
for each experimental run to assess potential synergistic 
effects of combined HDAC inhibitor/5-aza-cytidine 
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